Although insulin is the gold standard treatment during pregnancy, the risk of hypoglycemia and weight gain, as well as the financial burden, maintenance requirements and patient education time, hinder patient compliance and impede treatment acceptance [1]. This evidence concerns the gene INS and Hypoglycemia.